|
Bone Marrow and Peripheral Stem Cell Transplantation in Treating Patients With Hematologic Cancer Clinical Trials Data presented on Clinical Trials Search is not meant to be a substitute for qualified health advice, visits or treatment with a real mD. We are not doctors. Always consult your doctor about Bone Marrow and Peripheral Stem Cell Transplantation in Treating Patients With Hematologic Cancer conditions. Clinical Trials Search.org is a site devoted to listing clinical research studies in human subjects. Bone Marrow and Peripheral Stem Cell Transplantation in Treating Patients With Hematologic Cancer Clinical research trials and Bone Marrow and Peripheral Stem Cell Transplantation in Treating Patients With Hematologic Cancer healthcare trials happen in many of places across the United States. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials generally assess the effectivity of new drugs. The purpose of the studies / projects is to solve particular human medical questions. Clinical trials are a popular way for doctors, government agencies, and private sector companies to discover cures for all varieties of conditions, such as Bone Marrow and Peripheral Stem Cell Transplantation in Treating Patients With Hematologic Cancer. Bone Marrow and Peripheral Stem Cell Transplantation in Treating Patients With Hematologic Cancer Clinical Trials and other clinical trials allow volunteers to have health treatment alternatives before they are available to the masses. Some times the human subjects obtain treatment for without cost, and sometimes they are compensated for their time. Occasionally there is a cost for a Bone Marrow and Peripheral Stem Cell Transplantation in Treating Patients With Hematologic Cancer clinical trial. Test subjects oftentimes receive the most effective healthcare possible for their Bone Marrow and Peripheral Stem Cell Transplantation in Treating Patients With Hematologic Cancer condition. Dangers are a reality, however, and may include extra or frequent physician visits, healthcare dangers (possibly life-jeopardising), and/or the treatment being uneffective. Trials are federally governed with rigorous guidelines to protect clinical trials patients.
|
|
|
|
|
|
|
Home > "B" Clinical Trials Conditions > Bone Marrow and Peripheral Stem Cell Transplantation in Treating Patients With Hematologic Cancer  Bone Marrow and Peripheral Stem Cell Transplantation in Treating Patients With Hematologic Cancer
Bone Marrow and Peripheral Stem Cell Transplantation in Treating Patients With Hematologic Cancer
For Condition: Lymphoma,Multiple Myeloma,Leukemia
Status: Completed
Sponsor(s): National Cancer Institute (NCI) , Robert H. Lurie Cancer Center
Synopsis: RATIONALE: Bone marrow and peripheral stem cell transplantation may be able to replace immune cells that were destroyed by chemotherapy or radiation therapy used to kill tumor cells. PURPOSE: Phase I trial to study the effectiveness of bone marrow and peripheral stem cell transplantation in treating patients who have hematologic cancer.
Details: OBJECTIVES: I. Determine the toxicity of unmanipulated bone marrow augmented with CD34+ enriched peripheral blood stem cells in patients with hematologic malignancies undergoing allogeneic transplantation. II. Evaluate this treatment regimen in terms of kinetics of hematopoietic engraftment, infection, severity of graft-vs-host disease, relapse rate, and cost effectiveness in this patient population. PROTOCOL OUTLINE: Patients undergo allogeneic transplantation comprising unmanipulated bone marrow with filgrastim (G-CSF)-mobilized, CD34+ enriched peripheral blood stem cells on day 0. Patients receive graft-vs-host disease prophylaxis comprising cyclosporine IV over 24 hours on day -1 and methylprednisolone IV or oral prednisone daily on days 7-65. Patients also receive G-CSF subcutaneously daily until blood counts recover. Patients are followed weekly for 3 months, at 6 months and 1 year, and then annually for 5 years. PROJECTED ACCRUAL: A total of 30-60 patients will be accrued for this study.
Eligibility:
Study Type: Interventional, Educational/Counseling/Training
Minimum Age/Maximum Age: 10 Years/65 Years
Genders:
Protocol Entry Criteria: PROTOCOL ENTRY CRITERIA: --Disease Characteristics-- - Diagnosed hematologic malignancy that is eligible for an active allogeneic bone marrow transplantation protocol and leukemia, lymphoma, myeloma, and aplastic anemia treatment protocols - HLA-identical or one antigen-mismatched related donor --Prior/Concurrent Therapy-- - See Disease Characteristics --Patient Characteristics-- - Age: 10 to 65 - Performance status: Not specified - Life expectancy: Not specified - Hematopoietic: Not specified - Hepatic: Not specified - Renal: Not specified - Other: No known sensitivity to E. coli derivatives
Total Enrollment:
Location and Contact Information:
Overall Study Official:
RichardBurt, Study Chair, Robert H. Lurie Cancer Center
Robert H. Lurie Comprehensive Cancer Center, Northwestern University
Chicago, Illinois, 60611-3013
United States
Additional Information:
Study ID Numbers: CDR0000067474; NU-96H4,NCI-G99-1660
Study Start Date: October 1999
Record last reviewed: May 2003
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00004232
Other Lymphoma Studies:
1. Arsenic Trioxide With or Without Tretinoin in Treating Patients With Hematologic Cancer That Has Not Responded to Previous Therapy
2. Comparison of Nutritional Supplements in Preventing Weight Loss in Patients With Cancer
3. ZD0473 and Doxorubicin in Treating Patients With Advanced Solid Tumors or Lymphoma
4. Denileukin Diftitox in Treating Patients With Non-Hodgkin's Lymphoma
5. Mycophenolate Mofetil, Tacrolimus, Daclizumab, and Donor Peripheral Stem Cell Transplantation in Treating Patients With Hematologic Cancer
Related Studies:
Other Lymphoma Clinical Trials
Other Illinois Clinical Trials
Other Chicago Clinical Trials
Bone Marrow and Peripheral Stem Cell Transplantation in Treating Patients With Hematologic Cancer
|
|
|
|
|
|
|
|
